BNTX BioNTech SE

BioNTech to Report Second Quarter 2022 Financial Results and Operational Update on August 8, 2022

BioNTech to Report Second Quarter 2022 Financial Results and Operational Update on August 8, 2022

Mainz, Germany, July 25, 2022 (GLOBE NEWSWIRE) – (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2022 on Monday, August 8th, 2022. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the second quarter 2022.

To access the live conference call via telephone, please register via this . Once registered, dial-in numbers and a pin will be provided. It is recommended to register at least a day in advance.

The slide presentation and audio of the webcast will be available via this .

Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page of the Investor Relations section of the Company’s website at . A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call.

About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.

For more information, please visit .

BioNTech Contacts

Investor Relations

Sylke Maas, Ph.D.

+49 (0)6131 9084 1074

Media Relations

Jasmina Alatovic

+49 (0)6131 9084 1513



EN
25/07/2022

Underlying

BNTXBioNTech SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioNTech SE

 PRESS RELEASE
Free
BNTX BIONTECH SE

Erste Ergebnisse aus BioNTechs und BMS’ globaler Phase-2-Studie mit bi...

Erste Ergebnisse aus BioNTechs und BMS’ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig zeigten ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem dreifach negativem Brustkrebs Zwischenergebnisse der globalen klinischen Phase-2-Studie bei lokal fortgeschrittenem/metastasiertem dreifach negativem Brustkrebs (triple-negative breast cancer, „TNBC“) zeigten eine ermutigende Anti-Tumor-Aktivität für Pumitamig (BNT327/BMS986545) in Kombination mit Chemotherapie bei Patientinnen und Patienten in der Erst- oder ZweitlinienbehandlungPumitamig in Kombination m...

December 9, 2025 1 EN
 PRESS RELEASE
Free
BNTX BIONTECH SE

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data fo...

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chemotherapy in first- and second-line patientsPumitamig plus chemotherapy achieved confirmed objective response rate (cORR) of 61.5%, unconfirmed ORR (uORR) of 71.8% and disease control rate (DCR) of 92.3% irrespec...

December 9, 2025 1 EN
 PRESS RELEASE
Free
BNTX BIONTECH SE

BioNTechs und OncoC4s selektiver Treg-Modulatorkandidat Gotistobart er...

BioNTechs und OncoC4s selektiver Treg-Modulatorkandidat Gotistobart erzielte klinisch relevanten Gesamtüberlebensvorteil bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge Der selektive Treg-Modulatorkandidat Gotistobart (BNT316/ONC-392) zeigte eine Verringerung des Sterberisikos um mehr als die Hälfte im Vergleich zur Standard-Chemotherapie sowie ein kontrollierbares Sicherheitsprofil im ersten von zwei Abschnitten der globalen, klinischen Phase-3-Studie PRESERVE-003 bei Patientinnen und Patienten mit Plattenepithelkarzinom der Lunge (squamous non-small c...

December 6, 2025 1 EN
 PRESS RELEASE
Free
BNTX BIONTECH SE

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Be...

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care chemotherapy and a manageable safety profile in the first of two stages of the global Phase 3 trial PRESERVE-003 in patients with squamous non-small cell lung cancer (“sqNSCLC”) who have progressed on prior immunotherapy plus chemotherapyMedian OS with gotistobart ha...

December 6, 2025 1 EN
 PRESS RELEASE
Free
BNTX BIONTECH SE

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

BioNTech Achieves Minimum Condition in CureVac Exchange Offer The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac’s issued and outstanding shares, tendered prior to the expiration of the initial offering periodThe subsequent offering period has commenced and will expire at 12:01 a.m. Eastern Time on Thursday, December 18, 2025  MAINZ, Germany, December 3, 2025 – (Nasdaq: BNTX, “BioNTech”) announced today that 184,071,410 shares of CureVac N.V. (Nasdaq: CVAC, “CureVac”), representing approximately 81.74% o...

December 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch